Novo Nordisk, the maker of Ozempic and Wegovy, has also jumped into the legal fight —this time by intervening in the OFA’s lawsuit against the FDA. The company supports the agency’s move to restrict ...

By embedding AI at the platform level, firms can also support new and emerging use cases without needing to invest in ...

The FDA and the manufacturer of Ozempic, Novo Nordisk are urging patients, doctors and pharmacies to check their Ozempic ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

Some of the more than a dozen states that cover GLP-1 drugs like Wegovy, Ozempic and Zepbound through Medicaid are scrambling ...

People are buying semaglutide and tirzepatide, the key ingredients in Ozempic and Zepbound, from unconventional sources. Doctors have safety concerns.

U.S. President Donald Trump’s administration has decided not to cover expensive, high-demand obesity treatments under the federal government's Medicare program. The Centers for Medicare and ...

President Donald Trump now faces one legal challenge to his historic tariffs — and even more lawsuits could be on the way. A nonprofit legal group, the New Civil Liberties Alliance, filed a ...

Wegovy and Zepbound both cost roughly $1,000 before insurance and other rebates. Allowing Medicare to cover those drugs and other weight loss medications could cost $35 billion over nine years ...